维得利珠单抗致34例不良反应文献分析

目的: 分析维得利珠单抗(vedolizumab,VDZ)所致不良反应(adverse drug reactions,ADRs)的特点,为临床用药提供参考。方法: 检索中国知网(CNKI)、万方医学网、维普网(VIP)、PubMed和Web of Science数据库收载的VDZ致ADRs的个案报道并进行分析。结果: 纳入VDZ致ADRs个案报道30篇共34例,其中男性16例,女性18例,年龄在19~49岁24例,发生时间主要集中在用药的前3个月,累及皮肤软组织、消化、呼吸、骨骼等多个系统。经停药或减量和(或)对症治疗后,30例好转,2例转为慢性病程,1例仍处于疾病活动期,1例死亡。结论: 临床医师和药师应关注VDZ致ADRs,做好用药监护和患者随访,保证临床用药安全。

Literature analysis of 34 cases of adverse drug reactions induced by vedolizumab

OBJECTIVE To analyze the characteristics of adverse drug reactions(ADRs) induced by vedolizumab(VDZ) and provide reference for clinical medication.METHODS Case reports of ADRs induced by VDZ were searched and analyzed from the databases of CNKI, WanFang Medical Network, VIP, PubMed and Web of Science.RESULTS A total of 34 cases of ADRs induced by VDZ were included in 30 case reports, including 16 males and 18 females, and 24 cases aged from 19 to 49 years.The occurrence time was mainly concentrated in the first 3 months of medication, involving skin and soft tissue, digestive, respiratory, skeletal and other systems.After drug withdrawal or dosage reduction and(or) symptomatic treatment, 30 cases improved, 2 cases changed to chronic course, 1 case was still in disease active stage, and 1 case died.CONCLUSION Clinicians and pharmacists should pay attention to the ADRs of VDZ, medication monitoring and patient follow-up to ensure the safety of clinical medication.